A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma
PHASE2
Rationale for the current trial is to demonstrate 24 hour bronchodilator ef...
Status
Completed
Location
205.420.43002 Boehringer Ingelheim Investigational Site
The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus
PHASE4
The primary objective of the trial is to show superiority in lung function ...
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma
PHASE2
The primary objective of this trial is to evaluate the safety and efficacy ...
Status
Completed
Location
205.443.12003 Boehringer Ingelheim Investigational Site
Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients
PHASE3
The objective of the trial is to compare the lung function profile of once ...
Status
Completed
Location
1237.11.32002 Boehringer Ingelheim Investigational Site
A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler
N/A
Open-label observational study which includes COPD patients that are receiv...